160 related articles for article (PubMed ID: 36114134)
1. SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.
Aldoss I; Pourhassan H; Douer D
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):787-794. PubMed ID: 36114134
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Schmiegelow K; Rank CU; Stock W; Dworkin E; van der Sluis I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):725-733. PubMed ID: 34511319
[TBL] [Abstract][Full Text] [Related]
3. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia.
Aldoss I; Douer D
Blood; 2020 Mar; 135(13):987-995. PubMed ID: 31977001
[TBL] [Abstract][Full Text] [Related]
4. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
5. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase: How to Better Manage Toxicities in Adults.
Pourhassan H; Douer D; Pullarkat V; Aldoss I
Curr Oncol Rep; 2023 Jan; 25(1):51-61. PubMed ID: 36449117
[TBL] [Abstract][Full Text] [Related]
7. Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Bade NA; Lu C; Patzke CL; Baer MR; Duong VH; Law JY; Lee ST; Sausville EA; Zimrin AB; Duffy AP; Lawson J; Emadi A
J Oncol Pharm Pract; 2020 Jan; 26(1):74-92. PubMed ID: 30917738
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
9. Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding.
Alqahtani A; Alhousari D; Ali A; Yaghmour G; Orgel E; Curran E; Stock W; Bhojwani D; Alachkar H
Expert Opin Drug Metab Toxicol; 2023; 19(6):357-366. PubMed ID: 37410014
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
11. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
13. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Burke PW; Hoelzer D; Park JH; Schmiegelow K; Douer D
ESMO Open; 2020 Oct; 5(5):e000858. PubMed ID: 33037033
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
15. Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
.
Thu Huynh V; Bergeron S
Clin J Oncol Nurs; 2017 Oct; 21(5):E248-E259. PubMed ID: 28945721
[TBL] [Abstract][Full Text] [Related]
16. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
17. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
18. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
Gibson A; Hernandez C; Tejada FNH; Kawedia J; Rytting M; Cuglievan B
Paediatr Drugs; 2021 Sep; 23(5):457-463. PubMed ID: 34351604
[TBL] [Abstract][Full Text] [Related]
19. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]